



MEDICAL BENEFIT MANAGEMENT PROGRAM SPECIALTY DRUG LIST

Effective April 1, 2023

As of April 1, 2015, providers must use the web-based ExpressPAth platform to obtain prior authorization of drug treatments.

Register at <https://www.express-path.com>. If you have questions, please call (877) 273-2122.



This drug list is also available online by going to the following site: <https://accredio.com/prescribers/1199>

The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program. The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program. Please call 646-473-7160 to initiate the prior authorization process.

The symbol ♦ next to a drug name indicates that this medication is subject to the eviCore Comprehensive Oncology Management Program for drugs prescribed in the treatment of cancer. Please contact (888) 910-1199 for additional assistance.

The symbol [ST] next to a drug name indicates that this medication is non-preferred. Step therapy is designed to provide safe, effective treatment while controlling prescription costs. With step therapy, you are required to try established, lower-cost, clinically appropriate alternatives before progressing to other, more costly medications, such as Preferred Brand-name Drugs.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|------------------|---|-------------------------|------------------|--|--------------|------------|--------------------|
| ABILIFY MAINTENA | ARIPIRAZOLE | MENTAL CONDITIONS | | | | YES | J0401 |
| ACETADOTE | ACETYLCYSTEINE | ANTIDOTES | | | | YES | J0132 |
| ACTEMRA♦ | TOCILIZUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J3262 |
| ADAKVEO | CRIZANLIZUMAB-TMCA | SICKLE CELL DISEASE | PA | | | YES | J0791 |
| ADBRY | TRALOKINUMAB-LDRM | ASTHMA & ALLERGY | PA | | | YES | C9399, J3590 |
| ADCIRCA | TADALAFIL | PULMONARY HYPERTENSION | PA | | | YES | J8499 |
| ADEMPAS | RIOCIGUAT | CIRCULATION DISORDERS | PA | | | YES | J8499 |
| ADIPEX-P | PHENTERMINE | WEIGHT LOSS | PA | | | YES | J8499 |
| ADVATE | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7192 |
| ADYNOVATE | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB PEGYLATED | HEMOPHILIA | | | | YES | J7207 |
| AFSTYLA | ANTIHEMOPHL FCTR (RECOMB) SINGLE CHAIN | HEMOPHILIA | | | | YES | J7210 |
| AIMOVIG | ERENUMAB | MIGRAINE | PA | | | YES | C9399, J3590 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|-----------------|------------------------------------|---|------------------|--|--------------|------------|----------------------------------|
| AJOVY | FREMANEZUMAB | MIGRAINE | PA | | | YES | J3031 |
| ALDURAZYME | LARONIDASE | ENZYME DEFICIENCIES | | CPA | | YES | J1931 |
| ALPHANATE | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7186 |
| ALPHANINE SD | FACTOR IX COMPLEX (HUMAN) | HEMOPHILIA | | | | YES | J7193 |
| ALPROLIX | FACTOR IX Fc FUSION PROTEIN RECOMB | HEMOPHILIA | | | | YES | J7201 |
| ALTUVIIIIO † | ANTIHEMOPHILIC FACTOR RECOMB | HEMOPHILIA | | | | YES | J7199 |
| ALYMSYS ♦ | BEVACIZUMAB-MALY | OPHTHALMIC CONDITIONS/CANCER | PA | | | YES | C9142 (Q5126 EFF: 1/1/23) |
| AMPYRA | DALFAMPRIDINE | MULTIPLE SCLEROSIS | PA | | | YES | J8499 |
| AMVUTTRA | VUTRISIRAN SODIUM | AMYLOIDOSIS | PA | | | YES | C9399, J3490 |
| ANDEXXA | COAGULATION FACTOR XA | HEMATOLOGY | | | | YES | J7169 |
| APOKYN | APOMORPHINE HCL | MISCELLANEOUS CNS DISORDERS | | | | YES | J0364 |
| APRETUDE | CABOTEGRAVIR | HIV | PA | | | YES | C9399, J3490 (J0739 EFF: 7/1/22) |
| ARALAST NP | ALPHA-1-PROTEINASE INHIBITOR | RESPIRATORY CONDITIONS | PA | | | YES | J0256 |
| ARANESP ♦ | DARBEPOETIN ALFA | BLOOD CELL DEFICIENCY | PA | | | YES | J0881 |
| ARCALYST | RILONACEPT | CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES | PA | | | YES | J2793 |
| ARISTADA | ARIPIRAZOLE LAUROXIL INJ | MENTAL CONDITIONS | | | | YES | J1944 |
| ARISTADA INITIO | ARIPIRAZOLE LAUROXIL INJ | MENTAL CONDITIONS | | | | YES | J1943 |
| ASCENIV | IMMUNE GLOBULIN – IV | IMMUNE DEFICIENCY | PA | | | YES | J1554 |
| ATGAM | LYMPHOCYTE IMMUNE GLOBULIN | TRANSPLANT | PA | | | YES | J7504 |
| AUBAGIO | TERIFLUNOMIDE | MULTIPLE SCLEROSIS | PA | | | YES | J8499 |
| AUSTEDO | DEUTETRABENAZINE | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J8499 |
| AVASTIN ♦ | BEVACIZUMAB | OPHTHALMIC CONDITIONS | PA | | | YES | C9257 |
| AVEED | TESTOSTERONE UNDECANOATE | ENDOCRINE DISORDERS | PA | | | YES | J3145 |
| AVONEX | INTERFERON BETA-1A | MULTIPLE SCLEROSIS | PA | | | YES | J1826, Q3027 |
| AVSOLA | INFLIXIMAB-AXXQ | INFLAMMATORY CONDITIONS | PA | | | YES | Q5121 |
| BELVIQ XR | LORCASERIN | WEIGHT LOSS | PA | | | YES | J8499 |
| BENEFIX | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7195 |
| BENLYSTA IV | BELIMUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J0490 |
| BENLYSTA SC | BELIMUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 |
| BENZPHETAMINE | BENZPHETAMINE | WEIGHT LOSS | PA | | | YES | J3490 |
| BEOVU | BROLUCIZUMAB-DBLL | OPHTHALMIC CONDITIONS | PA | | | YES | J0179 |
| BERINERT | C1 ESTERASE INHIBITOR | HEREDITARY ANGIOEDEMA | PA | | | YES | J0597 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|----------------------------|------------------------------|------------------------------------|------------------|--|--------------|------------|-------------------------------------|
| BETASERON | INTERFERON BETA-1B | MULTIPLE SCLEROSIS | PA | | | YES | J1830 |
| BEVACIZUMAB | BEVACIZUMAB | OPHTHALMIC CONDITIONS | PA | | | YES | C9257, J7999 |
| BIVIGAM | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1556 |
| BONIVA (IV) | IBANDRONATE | OSTEOPOROSIS | PA | | | YES | J1740 |
| BOTOX | BOTULINUM TOXIN A | NEUROMUSCULAR CONDITIONS | PA | | | YES | J0585 |
| BRINEURA | CERLIPONASE ALFA | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J0567 |
| BRIUMVI † | UBLITUXIMAB-XIYY | MULTIPLE SCLEROSIS | PA | | | YES | C9399, J3590 |
| BYOOVIZ † | RANIBIZUMAB-NUNA | OPHTHALMIC CONDITIONS | PA | | | YES | Q5124 |
| CABENUVA | CABOTEGRAVIR | HIV | PA | | | YES | J0741 |
| CABLIVI | CAPLACIZUMAB-YHDP | BLOOD CELL DEFICIENCY | PA | | | YES | C9047 |
| CALCIUM DISODIUM VERSENATE | EDETATE CALCIUM DISODIUM | ANTIDOTES | | | | YES | J0600 |
| CARIMUNE NF | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1566 |
| CELLCEPT | MYCOPHENOLATE MOFETIL | TRANSPLANT | | | | YES | J7517, J7599 |
| CEPROTIN | PROTEIN C CONCENTRATE, HUMAN | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J2724 |
| CERDELGA | ELIGLUSTAT | ENZYME DEFICIENCIES | | CPA | | YES | J8499 |
| CEREZYME | IMIGLUCERASE | ENZYME DEFICIENCIES | | CPA | | YES | J1786 |
| CHEMET | SUCCIMER | IRON TOXICITY | PA | | | YES | J8499 |
| CHENODAL | CHENODIOL | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | NO HCPC |
| CHORIONIC GONADOTROPIN | GONADOTROPIN, CHORIONIC | ENDOCRINE DISORDERS | | | | YES | J0725 |
| CIDOFOVIR | CIDOFOVIR | VIRAL INFECTIONS | | | | YES | J0740 |
| CIMERLI † | RANIBIZUMAB-EQRN | OPHTHALMIC CONDITIONS | PA | | | YES | C9399, J3590 (Q5128 EFF: 4/1/23) |
| CIMZIA | CERTOLIZUMAB PEGOL | INFLAMMATORY CONDITIONS | PA | | | YES | J0717 |
| CINQAIR | RESLIZUMAB | RESPIRATORY CONDITIONS | PA | | | YES | C9481, J2786 |
| CINRYZE | C1 ESTERASE INHIBITOR | HEREDITARY ANGIOEDEMA | PA | | | YES | J0598 |
| CLEVIPREX | CLEVIDIPINE | CAARDIOVASCULAR DISEASE | | | | YES | C9248 |
| COAGADEX | FACTOR X HUMAN | HEMOPHILIA | | CPA | | YES | J7175 |
| CONTRAVE | NALTREXONE/BUPROPRION | WEIGHT LOSS | PA | | | YES | J3490 |
| COPAXONE | GLATIRAMER ACETATE | MULTIPLE SCLEROSIS | PA | | | YES | J1595 |
| CORIFACT | FACTOR XIII | HEMOPHILIA | | | | YES | J7180 |
| CORTROPHIN GEL | REPOSITORY CORTICOTROPIN | MISCELLANEOUS CONDITIONS | PA | | | YES | J3490 |
| COSENTYX | SECUKINUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 |
| CRESEMBA | ISAVUCONAZONIUM SULFATE | ANTIFUNGAL AGENTS | | | | YES | J1833 |

† Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|----------------------|-------------------------------------|------------------------------------|------------------|--|--------------|------------|----------------------------------|
| CROFAB | CROTALIDAE POLYVALENT IMMUNE FAB | ANTIDOTES | | | | YES | J0840 |
| CRYSVITA◆ | BUROSUMAB-TWZA | METABOLIC DISORDER | PA | | | YES | J0584 |
| CUTAQUIG | IMMUNE GLOBULIN [HUMAN]-HIPP | IMMUNE DEFICIENCY | PA | | | YES | 90284, J3590 (J1551 EFF: 7/1/22) |
| CUVITRU | IMMUNE GLOBULIN - SQ | IMMUNE DEFICIENCY | PA | | | YES | J1555 |
| CYTOGAM | CYTOMEGALOVIRUS IMMUNE GLOB | IMMUNE DEFICIENCY | | CPA | | YES | 90291, J0850 |
| CYTOVENE | GANCICLOVIR | VIRAL INFECTIONS | | | | YES | J1570 |
| DALFAMPRIDINE | DALFAMPRIDINE | MULTIPLE SCLEROSIS | PA | | | YES | J8499 |
| DDAVP | DESMOPRESSIN ACETATE | ENDOCRINE DISORDERS | | | | YES | J2597 |
| DEPO-TESTOSTERONE | TESTOSTERONE CYPIONATE | ENDOCRINE DISORDERS | PA | | | YES | J1071 |
| DESFERAL | DEFEROXAMINE MESYLATE | IRON TOXICITY | | | | YES | J0895 |
| DESMOPRESSIN ACETATE | DESMOPRESSIN ACETATE | ENDOCRINE DISORDERS | | | | YES | J2597 |
| DEXTENZA | DEXAMETHASONE | OPHTHALMIC CONDITIONS | | | | YES | J1096 |
| DEXYCU | DEXAMETHASONE | OPHTHALMIC CONDITIONS | | | | YES | J1095 |
| DIETHYLPROPION | DIETHYLPROPION | WEIGHT LOSS | PA | | | YES | J3490 |
| DIGIFAB | DIGOXIN IMMUNE FAB | ANTIDOTES | | | | YES | J1162 |
| DOPTELET | AVATROMBOPAG | THROMBOCYTOPENIA | PA | | | YES | C9399, J8499 |
| DUOPA | CARBIDOPA/LEVADOPA | NEUROLOGICAL DISORDERS | | | | YES | J7340 |
| DUPIXENT | DUPILUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 |
| DUROLANE | SODIUM HYALURONATE, HYALURONIC ACID | OSTEOARTHRITIS | PA | | ST | YES | J7318 |
| DURYSTA | BIMATOPROSTIL | OPHTHALMIC CONDITIONS | PA | | | YES | J7351 |
| DYLOJECT | DICLOFENAC SODIUM INJ | PAIN MANAGEMENT | | | | YES | J1130 |
| DYSPORT | ABOBOTULINUMTOXINA | NEUROMUSCULAR CONDITIONS | PA | | | YES | J0586 |
| EGRIFTA | TESAMORELIN ACETATE | ENDOCRINE DISORDERS | PA | | | YES | C9399, J3490 |
| ELAPRASE | IDURSULFASE | ENZYME DEFICIENCIES | | CPA | | YES | J1743 |
| ELELYSO | TALIGLUCERASE ALFA | ENZYME DEFICIENCIES | | CPA | | YES | J3060 |
| ELOCTATE | FACTOR IX Fc FUSION PROTEIN RECOMB | HEMOPHILIA | | CPA | | YES | J7205 |
| EMFLAZA | FACTOR IX Fc FUSION PROTEIN RECOMB | MUSCULAR DYSTROPHY | PA | | | YES | J8499 |
| EMGALITY | GALCANEZUMAB | MIGRAINE | PA | | | YES | C9399, J3590 |
| EMPAVELI | PEGCETACOPLAN | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | | C9399, J3490 |
| ENBREL | ETANERCEPT | INFLAMMATORY CONDITIONS | PA | | | YES | J1438 |
| ENDARI | L-GLUTAMINE | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J8499 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|---------------------|--------------------------------|------------------------------------|------------------|--|--------------|------------|---|
| ENJAYMO | SUTINLIMAB-JOME | MISCELLANEOUS CONDITIONS | PA | | | YES | (C9094 EFF: 7/1/22); (J1302 EFF: 10/1/22) |
| ENSPRYNG | SATRALIZUMAB-MWGE | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | C9399, J3590 |
| ENTYVIO | VEDOLIZUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J3380 |
| EPCLUSA | SOFOBUVIR/VELPATASVIR | HEPATITIS C | PA | | | YES | J8499 |
| EPIDIOLEX | CANNABIDIOL | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J8499 |
| EPOGEN◆ | EPOETIN ALFA | BLOOD CELL DEFICIENCY | PA | | | YES | J0885, Q4081 |
| EPOPROSTENOL SODIUM | EPOPROSTENOL NA | PULMONARY HYPERTENSION | PA | | | YES | J1325 |
| ESBRIET | PIRFENIDONE | IDIOPATHIC PULMONARY FIBROSIS | PA | | | YES | J8499 |
| ESPEROCT | ANTIHEMOPHILIC FACTOR VIII | HEMOPHILIA | | | | YES | J7199 |
| EUFLEXXA | SODIUM HYALURONATE | OSTEOARTHRITIS | PA | | | YES | J7323 |
| EVENITY | ROMOSOZUMAB-AQQG | OSTEOPOROSIS | PA | | | YES | J3111 |
| EVKEEZA | EVINACUMAB-DGNB | HIGH BLOOD CHOLESTEROL | PA | | | YES | J1305 |
| EVRYSDI | RISDIPLAM | SPINAL MUSCULAR ATROPHY | | CPA | | NO | J8499 |
| EXJADE | DEFERASIROX | IRON TOXICITY | PA | | | YES | J8499 |
| EXTAVIA | INTERFERON BETA-1B | MULTIPLE SCLEROSIS | PA | | | YES | J1830 |
| EYLEA | AFLIBERCEPT | OPHTHALMIC CONDITIONS | PA | | | YES | J0178 |
| FABRAZYME | AGALSIDASE | ENZYME DEFICIENCIES | | CPA | | YES | J0180 |
| FASENRA | BENRALIZUMAB | RESPIRATORY CONDITIONS | PA | | | YES | J0517 |
| FEIBA NF | ANTI-INHIBITOR COAGULANT COMP. | HEMOPHILIA | | | | YES | J7198 |
| FENSOLVI | LEUPROLIDE ACETATE DEPOT | ENDOCRINE DISORDERS | PA | | | YES | J1951 |
| FERRIPROX | DEFERIPRONE | IRON TOXICITY | PA | | | YES | J8499 |
| FIBRYGA | FIBRINOGEN | HEMATOLOGY | | | | YES | J7177 |
| FIRAZYR | ICATIBANT ACETATE | HEREDITARY ANGIOEDEMA | PA | | | YES | J1744 |
| FIRDAPSE | AMIFAMPRIDINE | MUSCULAR DYSTROPHY | | CPA | | YES | J8499 |
| FLEBOGAMMA DIF | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1572 |
| FLOLAN | EPOPROSTENOL NA | PULMONARY HYPERTENSION | PA | | | YES | J1325 |
| FOLLISTIM AQ | FOLLITROPIN BETA, RECOMB | ENDOCRINE DISORDERS | | | | YES | S0128 |
| FORTEO | TERIPARATIDE | OSTEOPOROSIS | PA | | | YES | J3110 |
| FOSCAVIR | FOSCARNET SODIUM | VIRAL INFECTIONS | | | | YES | J1455 |
| FUZEON | ENFUVIRTIDE | HIV | | | | YES | J1324 |
| GALAFOLD | MIGALASTAT | ENZYME DEFICIENCIES | PA | | | YES | C9399, J8499 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|------------------|---------------------------------------|------------------------------------|------------------|--|--------------|------------|----------------------------------|
| GAMASTAN S-D | IMMUNE GLOBULIN - IM | IMMUNE DEFICIENCY | PA | | | YES | 90281, J1460, J1560 |
| GAMIFANT | EMAPALUMAB-LZSG | MISCELLANEOUS CONDITIONS | PA | | | YES | J9210 |
| GAMMAGARD LIQUID | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, 90284, J1569 |
| GAMMAGARD S-D | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1566 |
| GAMMAKED | IMMUNE GLOBULIN - IV/SQ | IMMUNE DEFICIENCY | PA | | | YES | 90283, 90284, J1561 |
| GAMMAPLEX | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1557 |
| GAMUNEX-C | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, 90284, J1561 |
| GEL-ONE | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7326 |
| GELSYN-3 | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7328 |
| GENOTROPIN | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| GENVISC 850 | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7320, Q9980 |
| GILENYA | FINGOLIMOD HYDROCHLORIDE | MULTIPLE SCLEROSIS | PA | | | YES | J8499 |
| GIVLAARI | GIVOSIRAN | MISCELLANEOUS CONDITIONS | PA | | | YES | J0223 |
| GLASSIA | ALPHA-1-PROTEINASE INHIBITOR | RESPIRATORY CONDITIONS | PA | | | YES | J0257 |
| GLATOPA | GLATIRAMER ACETATE | MULTIPLE SCLEROSIS | PA | | | YES | J1595 |
| GRASTEK | TIMOTHY GRASS POLLEN ALLERGEN EXTRACT | ASTHMA AND ALLERGY | PA | | | YES | J3590, C9399 |
| H.P. ACTHAR GEL | CORTICOTROPIN | MISCELLANEOUS CNS DISORDERS | PA | | | YES | J0800 |
| HAEGARDA | C1 ESTERASE INHIBITOR | HEREDITARY ANGIOEDEMA | PA | | | YES | J0599 |
| HARVONI | LEDIPASVIR/SOFOSBUVIR | HEPATITIS C | PA | | | YES | J8499 |
| HEMGENIX † | ETRANACOGENE DEZAPARVOVEC - DRLB | HEMOPHILIA | | CPA | | YES | C9399, J3590 (J1411 EFF: 4/1/23) |
| HELIXATE FS | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7192 |
| HEMLIBRA | EMICIZUMAB | HEMOPHILIA | | | | YES | J7170 |
| HEMOPIL M | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7190 |
| HEPAGAM B | HEP.B IMMUNE GLOB/MALTOSE | HEPATITIS B | | | | YES | J1571, J1573 |
| HETLIOZ | TASIMELTEON | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J8499 |
| HIZENTRA | IMMUNE GLOBULIN- SQ | IMMUNE DEFICIENCY | PA | | | YES | 90284, J1599 |
| HUMATE-P | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7187 |
| HUMATROPE | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| HUMIRA | ADALIMUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J0135 |
| HYALGAN | SODIUM HYALURONATE | OSTEOARTHRITIS | PA | | ST | YES | J7321 |

† Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|--------------------------------|---|---|------------------|--|--------------|------------|--|
| HYDROXYPROGESTERONE CAPROATE † | HYDROXYPROGESTERONE CAPROATE | MISCELLANEOUS SPECIALTY CONDITIONS | | | | | J1726 (FDA Withdrew from Market on 4/6/23) |
| HYMOVIS | HYALURONIC ACID | OSTEOARTHRITIS | PA | | ST | YES | C9471, J7322 |
| HYPERHEP B S-D | HEPATITIS B IMMUNE GLOBULIN | HEPATITIS B | | | | YES | 90371 |
| HYPERRAB S-D | RABIES IMMUNE GLOBULIN | IMMUNE DEFICIENCY | | | | YES | 90375 |
| HYQVIA | IMMUNE GLOBULIN - SQ | IMMUNE DEFICIENCY | PA | | | YES | J1575 |
| ICATIBANT | ICATIBANT | HEREDITARY ANGIOEDEMA | PA | | | YES | J1744 |
| IDELVION | FACTOR IX ALBUMIN FUSION PROTEIN RECOMB | HEMOPHILIA | | | | YES | J7202 |
| ILARIS | CANAKINUMAB | CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES | PA | | | YES | J0638 |
| ILUMYA | TILDRAKIZUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J3245 |
| ILUVIEN | FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT | OPHTHALMIC CONDITIONS | | | | YES | J7313 |
| IMCIVREE † | SETMELANOTIDE | ENDOCRINE DISORDERS | | CPA | | YES | J3490, J3590 |
| IMOGAM RABIES-HT | RABIES IMMUNE GLOBULIN | IMMUNE DEFICIENCY | | | | YES | 90376 |
| INCRELEX | MECASERMIN | GROWTH DEFICIENCY | PA | | | YES | J2170 |
| INFLECTRA | INFLIXIMAB-DYYB | INFLAMMATORY CONDITIONS | PA | | | YES | Q5103 |
| INGREZZA | VALBENAZINE | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J8499 |
| IXINITY | COAGULATION FACTOR IX RECOMB | HEMOPHILIA | | | | YES | J7195 |
| JADENU | DEFERASIROX | IRON TOXICITY | PA | | | YES | J8499 |
| JETREA | OCRIPLASMIN | OPHTHALMIC CONDITIONS | | | | YES | J7316 |
| JVI | ANTIHEMOPHILIC FACTOR, AHF, FACTOR VIII | HEMOPHILIA | | | | YES | J7208 |
| JUXTAPID | LOMITAPIDE | HYPERCHOLESTEROLEMIA | PA | | | YES | J8499 |
| JYNARQUE | TOLVAPTAN | MISCELLANEOUS CONDITIONS | PA | | | YES | J8499 |
| KALBITOR | ECALLANTIDE | HEREDITARY ANGIOEDEMA | PA | | | YES | J1290 |
| KALYDECO | IVACAFTOR | CYSTIC FIBROSIS | PA | | | YES | J8499 |
| KANUMA | SEBELIPASE ALFA | ENZYME DEFICIENCIES | | CPA | | YES | C9478, J2840 |
| KCENTRA | PROTHROMBIN COMPLEX HUMAN | HEMOPHILIA | | | | YES | J7168 |
| KENALOG | TRIAMCINOLONE ACETONIDE | INFLAMMATORY CONDITIONS | | | | YES | J3301 |
| KESIMPTA | OFATUMUMAB | MULTIPLE SCLEROSIS | PA | | | YES | J3490 |
| KEVZARA | SARILUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 |
| KINERET | ANAKINRA | INFLAMMATORY CONDITIONS | PA | | | YES | J3590 |

† Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|-----------------------|---------------------------------------|------------------------------------|------------------|--|--------------|------------|--|
| KOATE-DVI | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7190 |
| KOGENATE FS | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7192 |
| KORLYM | MIFEPRISTONE | ENDOCRINE DISORDERS | PA | | | YES | J8499 |
| KOVALTRY | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB | HEMOPHILIA | | | | YES | J7211 |
| KRYSTEXXA | PEGLOTICASE | GOUT | PA | | | YES | J2507 |
| KUVAN | SAPROPTERIN DIHYDROCHLORIDE | ENDOCRINE DISORDERS | PA | | | YES | J8499 |
| KYLEENA | LEVONORGESTREL | CONTRACEPTIVE | | | | YES | J7296 |
| LAMZEDE † | VELMANASE ALFA | ENZYME DISORDERS | | CPA | | YES | C9399, J3590 |
| LANREDOTIDE (CIPLA) ◆ | LANREOTIDE | ENDOCRINE DISORDERS | PA | | | YES | J1932 |
| LANREOTIDE | LANREOTIDE | ENDOCRINE DISORDERS | PA | | | YES | J1930 |
| LEMTRADA | ALEMTUZUMAB | MULTIPLE SCLEROSIS | PA | | | YES | J0202 |
| LEQVIO | INCLISIRAN | HIGH BLOOD CHOLESTEROL | PA | | | YES | C9399, J3490 (J1306 EFF: 7/1/22) |
| LETAIRIS | AMBRISENTAN | PULMONARY HYPERTENSION | PA | | | YES | J8499 |
| LILETTA | LEVONORGESTREL | CONTRACEPTIVE | | | | YES | J7297 |
| LOMAIRA | PHENTERMINE | WEIGHT LOSS | PA | | | YES | J3490 |
| LUCENTIS | RANIBIZUMAB | OPHTHALMIC CONDITIONS | PA | | | YES | J2778 |
| LUMIZYME | ALGLUCOSIDASE ALFA | ENZYME DEFICIENCIES | | CPA | | YES | J0221 |
| LUPANETA | LEUPROLIDE DEPOT/ NORETHINDRONE | MISCELLANEOUS CONDITIONS | PA | | | YES | C9399, J3490 |
| LUPRON DEPOT PED ◆ | LEUPROLIDE DEPOT | MISCELLANEOUS CONDITIONS | PA | | | YES | J1950 |
| LUPRON DEPOT ◆ | LEUPROLIDE DEPOT | MISCELLANEOUS CONDITIONS | PA | | | YES | J1950, J9217 |
| LUXTURNA | VORETIGENE NAPARVOVEC | OPHTHALMIC CONDITIONS | PA | | | YES | J3398 |
| MAKENA † | HYDROXYPROGESTERONE CAPROATE | MISCELLANEOUS SPECIALTY CONDITIONS | | | | | J1726 (FDA Withdrew from Market on 4/6/23) |
| MAVYRET | GLECAPREVIR/PIBRENTASVIR | HEPATITIS C | PA | | | YES | J8499 |
| MIACALCIN | CALCITONIN | BONE CONDITIONS | | | | YES | J0630 |
| MIRCERA | EPOETIN BETA | BLOOD CELL DEFICIENCY | PA | | | YES | J0887, J0888 |
| MIRENA | LEVONORGESTREL | CONTRACEPTIVE | | | | YES | J7298 |
| MONOCLATE-P | FACTOR VIII (ANTIHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7190 |
| MONONINE | FACTOR IX COMPLEX (HUMAN) | HEMOPHILIA | | | | YES | J7193 |
| MONOVISC | SODIUM HYALURONATE | OSTEOARTHRITIS | PA | | | YES | J7327 |
| MOUNJARO | TIRZEPATIDE | DIABETES | PA | | | YES | J3490 |
| MULPLETA | LUSUTROMBOPAG | THROMBOCYTOPENIA | PA | | | YES | C9399, J8499 |
| MVASI ◆ | BEVACIZUMAB-AWWB | OPHTHALMIC CONDITIONS | PA | | | YES | Q5107 |
| MYALEPT | METRELEPTIN | LIPODYSTROPHY | PA | | | YES | J3590, C9399 |
| MYCOPHENOLATE MOFETIL | MYCOPHENOLATE MOFETIL | TRANSPLANT | | | | YES | J7517 |

† Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|--------------------|--|-------------------------------|------------------|--|--------------|------------|--------------------|
| MYFORTIC | MYCOPHENOLATE SODIUM | TRANSPLANT | | | | YES | J7518 |
| MYOBLOC | BOTULINUM TOXIN TYPE B | NEUROMUSCULAR CONDITIONS | PA | | | YES | J0587 |
| NABI-HB | HEPATITIS B IMMUNE GLOBULIN | HEPATITIS B | | | | YES | 90371 |
| NAGLAZYME | GALSULFASE | ENZYME DEFICIENCIES | | CPA | | YES | J1458 |
| NATPARA | PARATHYROID HORMONE | ENDOCRINE DISORDERS | PA | | | YES | C9399, J3590 |
| NEUPOGEN◆ | FILGRASTIM, G-CSF | BLOOD CELL DEFICIENCY | PA | | | YES | J1442 |
| NEXPLANON | ETONOGESTREL | CONTRACEPTIVE | | | | YES | J7307 |
| NEXVIAZYME | AVALGLUCOSIDAE ALFA-NGPT | ENZYME DEFICIENCIES | | CPA | | YES | J0219 |
| NIVESTYM◆ | FILGRASTIM-AAFI | BLOOD CELL DEFICIENCY | PA | | | YES | Q5110 |
| NORDITROPIN | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| NOVAREL | GONADOTROPIN, CHORIONIC | ENDOCRINE DISORDERS | | | | YES | J0725 |
| NOVOEIGHT | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB | HEMOPHILIA | | | | YES | J7182 |
| NOVOSEVEN RT | FACTOR VIIA, RECOMB (BHK CELLS) | HEMOPHILIA | | | | YES | J7189 |
| NPLATE | ROMIPLOSTIM | THROMBOCYTOPENIA | PA | | | YES | J2796 |
| NUCALA | MEPOLIZUMAB | RESPIRATORY CONDITIONS | PA | | | YES | C9473, J2182 |
| NULIBRY | FOSDENOPTERIN | ENZYME DEFICIENCIES | PA | | | YES | C9399, J3590 |
| NULOJIX | BELATACEPT | TRANSPLANT | PA | | | YES | J0485 |
| NUPLAZID | PIMAVANSERIN | MENTAL/NEURO DISORDERS | PA | | | YES | J8499 |
| NUTROPIN | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| NUVARING | ETONOGESTREL/ETHYNYL ESTRADIOL | CONTRACEPTIVE | | | | YES | J7295 |
| NUWIQ | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB | HEMOPHILIA | | | | YES | J7209 |
| OBIZUR | ANTIHEMOPHL FCTR (RECOMB) PORCINE SEQUENCE | HEMOPHILIA | | | | YES | J7194, J7188 |
| OCREVUS | OCRELIZUMAB | MULTIPLE SCLEROSIS | PA | | | YES | J2350 |
| OCTAGAM | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1568 |
| OCTREOTIDE ACETATE | OCTREOTIDE | ENDOCRINE DISORDERS | | | | YES | J2354 |
| OFEV | NINTEDANIB | IDIOPATHIC PULMONARY FIBROSIS | PA | | | YES | J8499 |
| OLUMIANT | BARICITINIB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J8499 |
| OMNITROPE | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| ONPATTRO | PATISIRAN | AMYLOIDOSIS | PA | | | YES | J0222 |
| OPSUMIT | MACITENTAN | PULMONARY HYPERTENSION | PA | | | YES | J8499 |
| ORALAIR | MIXED GRASS POLLENS ALLERGENS EXTRACT | ASTHMA AND ALLERGY | PA | | | YES | C9399, J3590 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|--------------------------|-------------------------------------|------------------------------------|------------------|--|--------------|------------|--------------------|
| ORENCIA | ABATACEPT/MALTOSE | INFLAMMATORY CONDITIONS | PA | | | YES | J0129 |
| ORENITRAM | TREPROSTINIL | PULMONARY HYPERTENSION | PA | | | YES | J8499 |
| ORKAMBI | LUMACAFTOR/IVACAFTOR | CYSTIC FIBROSIS | PA | | | YES | J8499 |
| ORTHOVISC | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | | YES | J7324 |
| OTEZLA | APREMILAST | INFLAMMATORY CONDITIONS | PA | | | YES | J8499 |
| OTIPRIO | CIPROFLOXACIN | INFECTIOUS DISEASE | | | | YES | J7342 |
| OXLUMO | LUMASIRAN | MISCELLANEOUS CONDITIONS | PA | | | YES | J0224 |
| OZURDEX | DEXAMETHASONE, INTRAVITREAL IMPLANT | OPHTHALMIC CONDITIONS | | | | YES | J7312 |
| PALYNZIQ | PEGVALIASE | METABOLIC DISORDER | PA | | | YES | C9399, J3590 |
| PANZYGA | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1599 |
| PARAGARD | INTRAUTERINE COPPER IUD | CONTRACEPTIVE | | | | YES | J7300 |
| PARSABIV | ETELCALCETIDE | HORMONAL SUPPLEMENTATION | | | | YES | J0606 |
| PEGASYS ♦ | PEGINTERFERON ALFA-2A | HEPATITIS C | PA | | | YES | S0145, J3590 |
| PEGINTRON ♦ | PEGINTERFERON ALFA-2A | HEPATITIS C | PA | | | YES | S0148, J3590 |
| PHENDIMETRAZINE | PHENDIMETRAZINE | WEIGHT LOSS | PA | | | YES | J3490 |
| PHOTREXA | RIBOFLAVIN 5 PHOSPHATE | OPHTHALMIC CONDITIONS | | | | YES | J2787 |
| PLEGRIDY | PEGINTERFERON BETA-1A | MULTIPLE SCLEROSIS | PA | | | YES | C9399, J3590 |
| PRALUENT | ALIROCUMAB | HYPERCHOLESTEROLEMIA | PA | | | YES | C9399, J3590 |
| PREGNYL | GONADOTROPIN, CHORIONIC | ENDOCRINE DISORDERS | | | | YES | J0725 |
| PRIALT | ZICONOTIDE ACETATE | PAIN MANAGEMENT | | | | YES | J2278 |
| PRIVIGEN | IMMUNE GLOBULIN - IV | IMMUNE DEFICIENCY | PA | | | YES | 90283, J1459 |
| PROBUPHINE IMPLANT | BUPRENORPHINE HCL | MISCELLANEOUS SPECIALTY CONDITIONS | | | | YES | J0570 |
| PROCRIT ♦ | EPOETIN ALFA | BLOOD CELL DEFICIENCY | PA | | | YES | J0885, Q4081 |
| PROFILNINE/PROFILNINE SD | FACTOR IX COMPLEX (HUMAN) | HEMOPHILIA | | | | YES | J7194 |
| PROGESTERONE | PROGESTERONE | ENDOCRINE DISORDERS | | | | YES | J2675 |
| PROGRAF | TACROLIMUS | TRANSPLANT | | | | YES | J7507, J7525 |
| PROLASTIN-C | ALPHA-1-PROTEINASE INHIBITOR | RESPIRATORY CONDITIONS | PA | | | YES | J0256 |
| PROLIA | DENOSUMAB | OSTEOPOROSIS | PA | | | YES | J0897 |
| PROMACTA | ELTROMBOPAG OLAMINE | THROMBOCYTOPENIA | PA | | | YES | J8499 |
| PULMOZYME | DEOXYRIBONUCLEASE | RESPIRATORY CONDITIONS | PA | | | YES | J7639 |
| QSYMIA | PHENTERMINE; TOPIRAMATE | WEIGHT LOSS | PA | | | YES | J8499 |
| RADICAVA | EDAVARONE | AMYOTROPHIC LATERAL SCLEROSIS | PA | | | YES | J1301 |
| RAPAMUNE | SIROLIMUS | TRANSPLANT | | | | YES | J7520 |
| RAPIVAB | PERAMIVIR | ANTIVIRAL AGENTS | | | | YES | J2547 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|-------------------|---|--------------------------|------------------|--|--------------|------------|-----------------------------|
| REBETOL | RIBAVIRIN | HEPATITIS C | PA | | | YES | J8499 |
| REBIF | INTERFERON BETA-1A/ALBUMIN | MULTIPLE SCLEROSIS | PA | | | YES | Q3028 |
| REBINYN | FACTOR IX (ANTIHEMOPHILIC FACTOR, RECOMBINANT) | HEMOPHILIA | | | | YES | J7203 |
| REBLOZYL ♦ | LUSPATERCEPT-AAMT | BLOOD MODIFYING | PA | | | YES | J0896 |
| RECLAST | ZOLEDRONIC ACID | OSTEOPOROSIS | PA | | | YES | J3489 |
| RECOMBINATE | FACTOR VIII (ANTIHEMOPHL FCTR) RECOMB | HEMOPHILIA | | | | YES | J7192 |
| RELEUKO ♦ | FILGRASTIM-AYOW | BLOOD CELL DEFICIENCY | PA | | | YES | C9096, (Q5125 EFF: 10/1/22) |
| REMICADE | INFLIXIMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J1745 |
| REMODULIN | TREPROSTINIL SODIUM | PULMONARY HYPERTENSION | PA | | | YES | J3285 |
| RENFLXIS | INFLIXIMAB-ABDA | INFLAMMATORY CONDITIONS | PA | | | YES | Q5104 |
| REPATHA | EVOLOCUMAB | HYPERCHOLESTEROLEMIA | PA | | | YES | C9399, J3590 |
| RETACRIT ♦ | EPOETIN ALFA | BLOOD CELL DEFICIENCY | PA | | | YES | Q5105, Q5106 |
| RETAVASE | PERAMIVIR | VIRAL INFECTIONS | | | | YES | J2993 |
| REVATIO | SILDENAFIL CITRATE | PULMONARY HYPERTENSION | PA | | | YES | J3490, J8499 |
| RIABNI ♦ | RITUXIMAB-ARRX | INFLAMMATORY CONDITIONS | PA | | | YES | Q5123 |
| RIASTAP | FIBRINOGEN | HEMATOLOGY | | | | YES | J7178 |
| RIBAPAK | RIBAVIRIN | HEPATITIS C | PA | | | YES | J8499 |
| RIBAVIRIN | RIBAVIRIN | HEPATITIS C | PA | | | YES | J8499 |
| RITUXAN ♦ | RITUXIMAB | INFLAMMATORY CONDITIONS | PA | | ST | YES | J9312 |
| RIXUBIS | FACTOR IX, (ANTIHEMOPHILIC FACTOR, RECOMBINANT) | HEMOPHILIA | | | | YES | J7200 |
| RUCONEST | C1 ESTERASE INHIBITOR | HEREDITARY ANGIOEDEMA | PA | | | YES | J0596 |
| RUXIENCE ♦ | RITUXIMAB-PVVR | INFLAMMATORY CONDITIONS | PA | | | YES | Q5119 |
| RYPLAZIM | PLASMINOGEN, HUMAN-TVMH | HEMATOLOGY | PA | | | YES | C9090 (J2998 EFF: 7/1/22) |
| SAIZEN | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| SANDOSTATIN ♦ | OCTREOTIDE | ENDOCRINE DISORDERS | | | | YES | J2354 |
| SANDOSTATIN LAR ♦ | OCTREOTIDE | ENDOCRINE DISORDERS | | | | YES | J2353 |
| SAPHNELO | ANIFROLUMAB-FNIA | LUPUS | PA | | | YES | J0491 |
| SAXENDA | LIRAGLUTIDE | WEIGHT LOSS | PA | | | YES | J3490 |
| SCENESSE | AFAMELANOTIDE | MISCELLANEOUS CONDITIONS | PA | | | YES | J7352 |
| SEROSTIM | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|--------------------|-----------------------------|------------------------------------|------------------|--|--------------|------------|----------------------------------|
| SEVENFACT | FACTOR VIIA RECOMBINANT | HEMOPHILIA | | | | YES | J7212 |
| SIGNIFOR LAR | PASIREOTIDE DIASPARTATE INJ | ENDOCRINE DISORDERS | PA | | | YES | C9454, J2502 |
| SILDENAFIL CITRATE | SILDENAFIL CITRATE | PULMONARY HYPERTENSION | PA | | | YES | J3490, J8499 |
| SILIQ | BRODALUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399 |
| SIMPONI | GOLIMUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 |
| SIMPONI ARIA | GOLIMUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J1602 |
| SIMULECT | BASILIXIMAB | TRANSPLANT | | | | YES | J0480 |
| SINUVA | MOMETASONE | RESPIRATORY CONDITIONS | | | | YES | J7402 |
| SKYLA | LEVONORGESTREL | CONTRACEPTIVE | | | | YES | J7301 |
| SKYRIZI | RISANKIZUMAB-RZAA | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 |
| SKYRIZI IV † | RISANKIZUMAB-RZAA | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 (J2327 EFF: 1/1/23) |
| SKYSONA | ELIVALDOGENE AUTOTEMCEL | NEUROLOGICAL DISORDERS | | CPA | | YES | C9399, J3590 |
| SKYTROFA | LONAPEGSOMATROPIN-TCGD | GROWTH DEFICIENCIES | PA | | | YES | C9399, J3590 |
| SODIUM HYALURONATE | SODIUM HYALURONATE | OSTEOARTHRITIS | PA | | ST | YES | C9399, J3490 |
| SOLESTA | DEXTRANOMER/HYALURONATE/SOD | MISCELLANEOUS SPECIALTY CONDITIONS | | | | YES | L8605 |
| SOLIRIS | ECULIZUMAB | BLOOD MODIFYING | PA | | | YES | J1300 |
| SOMATULINE DEPOT ♦ | LANREOTIDE ACETATE | ENDOCRINE DISORDERS | | | | YES | J1930 |
| SOVALDI | SOFOSBUVIR | HEPATITIS C | PA | | | YES | J8499 |
| SPEVIGO † | SPESOLIMAB-SBZO | INFLAMMATORY CONDITIONS | PA | | | YES | C9399, J3590 (J1747 EFF: 4/1/23) |
| SPINRAZA | NUSINERSEN | NEUROMUSCULAR CONDITIONS | | CPA | | YES | J2326 |
| SPRAVATO | ESKETAMINE | MISCELLANEOUS CONDITIONS | PA | | | YES | S0013 |
| STELARA | USTEKINUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J3357 |
| STELARA IV | USTEKINUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J3358 |
| STRENSIQ | ASFOTASE ALFA | ENZYME DEFICIENCIES | PA | | | YES | C9399, J3590 |
| SUNLENCA † | LENACAPAVIR | HIV | PA | | | YES | C9399, J3490 |
| SUPARTZ FX | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7321 |
| SUSVIMO | RANIBIZUMAB | OPHTHALMIC CONDITIONS | PA | | | YES | J2779 |
| SYFOVRE † | PEGCECTACOPLAN | OPHTHALMIC CONDITIONS | PA | | | YES | C9399, J3490 |
| SYMDEKO | TEZACAFTOR/IVACAFTOR | CYSTIC FIBROSIS | PA | | | YES | J8499 |
| SYNAGIS | PALIVIZUMAB | RSV PREVENTION | PA | | | YES | 90378 |

† Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

♦ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|------------------------|--------------------------------------|--------------------------|------------------|--|--------------|------------|-------------------------------------|
| SYNERCID | QUINUPRISTIN/DALFOPRISTIN | ANTIBIOTICS | | | | YES | J2770 |
| SYNVISC | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7325 |
| SYNVISC-ONE | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7325 |
| TACROLIMUS | TACROLIMUS | TRANSPLANT | | | | YES | J7507 |
| TADALAFIL | TADALAFIL | PULMONARY HYPERTENSION | PA | | | YES | J8499 |
| TAKHZYRO | LANADELUMAB | HEREDITARY ANGIOEDEMA | PA | | | YES | J0593 |
| TALTZ | IXEKIZUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | C9399 |
| TAVALISSE | FOSTAMATINIB | THROMBOCYTOPENIA | PA | | | YES | J8499 |
| TECFIDERA | DIMETHYL FUMARATE | MULTIPLE SCLEROSIS | PA | | | YES | J8499 |
| TEFLARO | CEFTAROLINE | INFECTIOUS DISEASE | | | | YES | J0712 |
| TEGSEDI | INOTERSEN | AMYLOIDOSIS | PA | | | YES | C9399, J3490 |
| TEPEZZA | TEPROTUMUMAB-TRBW | OPHTHALMIC CONDITIONS | PA | | | YES | J3241 |
| TESTOPEL | TESTOSTERONE PELLETT | ENDOCRINE DISORDERS | PA | | | YES | J3490, S0189 |
| TESTOSTERONE ENANTHATE | TESTOSTERONE ENANTHATE | ENDOCRINE DISORDERS | PA | | | YES | J3121 |
| TEZSPIRE | TEZEPELUMAB-EKKO | ASTHMA & ALLERGY | PA | | | YES | C9399, J3590 (J2356 EFF: 7/1/22) |
| THYMOGLOBULIN | LYMPHOCYTE IMMUNE GLOBULIN | TRANSPLANT | | | | YES | J7511 |
| TOBI | TOBRAMYCIN | RESPIRATORY CONDITIONS | | | | YES | J3535, J7682 |
| TRACLEER | BOSENTAN | PULMONARY HYPERTENSION | PA | | | YES | J8499 |
| TREMFYA | GUSELKUMAB | INFLAMMATORY CONDITIONS | PA | | | YES | J1628 |
| TRETEN | FACTOR XIII A-SUBUNIT, (RECOMBINANT) | HEMOPHILIA | | | | YES | J7181 |
| TRILURON | SODIUM HYALURONATE | OSTEOARTHRITIS | PA | | ST | YES | J7332 |
| TRIPTODUR | TRIPTORELIN | MISCELLANEOUS CONDITIONS | PA | | | YES | J3316 |
| TRIVISC | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7329 |
| TROGARZO | IBALIZUMAB | HIV | PA | | | YES | J1746 |
| TRUXIMA◆ | RITUXIMAB - ABBS | INFLAMMATORY CONDITIONS | PA | | | YES | Q5115 |
| TYGACIL | TIGECYCLINE | ANTIBIOTICS | | | | YES | J3243 |
| TYMLOS | ABALOPARATIDE | OSTEOPOROSIS | PA | | | YES | C9399 |
| TYSABRI | NATALIZUMAB | MULTIPLE SCLEROSIS | PA | | | YES | J2323 |
| TYVASO | TREPROSTINIL (TYVASO) | PULMONARY HYPERTENSION | PA | | | YES | J7686 |
| TZIELD✦ | TEPLIZUMAB - MZVW | ENDOCRINE DISORDERS | PA | | | YES | C9399, J3590 (C9149 EFF: 4/1/23) |
| ULTOMIRIS | RAVULIZUMAB-CWVZ | BLOOD MODIFYING | PA | | | YES | J1303 |
| UPLIZNA | INEBILIZUMAB-CWVZ | MISCELLANEOUS CONDITIONS | PA | | | YES | J1823 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|-----------------|--|------------------------------------|------------------|--|--------------|------------|--|
| UPTRAVI | SELEXIPAG | PULMONARY HYPERTENSION | PA | | | YES | J8499 |
| VABYSMO | FARICIMAB-SVOA | OPHTHALMIC CONDITIONS | PA | | | YES | (C9097 EFF: 7/1/22); (J2777 EFF: 10/1/22) |
| VAPRISOL | CONIVAPTAN HYDROCHLORIDE | HORMONAL SUPPLEMENTATION | | | | YES | C9488 |
| VEGZELMA◆✦ | BEVACIZUMAB-ADCD | OPHTHALMIC CONDITIONS/CANCER | PA | | | YES | C9399, J3590 (Q5129 EFF: 4/1/23) |
| VEKLURY | REMEDESIVIR | COVID-19 | PA | | | YES | J0248 |
| VELETRI | EPOPROSTENOL NA | PULMONARY HYPERTENSION | PA | | | YES | J1325 |
| VENTAVIS | ILOPROST | PULMONARY HYPERTENSION | PA | | | YES | Q4074 |
| VIEKIRA PAK | OMBITASVIR, PARITAPREVIR, AND RITONAVIR; DASABUVIR | HEPATITIS C | PA | | | YES | J8499 |
| VIMIZIM | ELOSULFASE ALFA | ENZYME DEFICIENCIES | | CPA | | YES | C9022, J1322 |
| VISCO-3 | HYALURONATE SODIUM | OSTEOARTHRITIS | PA | | ST | YES | J7321 |
| VISUDYNE | VERTEPORFIN | OPHTHALMIC CONDITIONS | | | | YES | J3396 |
| VIVITROL | NALTREXONE MICROSPHERES | MISCELLANEOUS CNS DISORDERS | | | | YES | J2315 |
| VONVENDI | VON WILLEBRAND FACTOR (RECOMBINANT) | HEMOPHILIA | | | | YES | J7179 |
| VOSEVI | SOFOBUVIR; VELPATASVIR; VOXILAPREVIR | HEPATITIS C | PA | | | YES | J8499 |
| VOXZOGO | VOSORITIDE | ENDOCRINE DISORDERS | PA | | | YES | C9399, J3590 |
| VPRIV | VELAGLUCERASE ALFA | ENZYME DEFICIENCIES | | CPA | | YES | J3385 |
| VYEPTI | EPTINEZUMAB-JJMR | MISCELLANEOUS CONDITIONS | PA | | | YES | J3032 |
| VYVGART | EFGARTIGIMOD ALFA-FCAB | MISCELLANEOUS CONDITIONS | PA | | | YES | C9399, J3590 (J9332 EFF: 7/1/22) |
| WILATE | VON WILLEBRAND FACTOR COMPLEX (HUMAN) | HEMOPHILIA | | | | YES | J7183 |
| XELJANZ | TOFACITINIB | INFLAMMATORY CONDITIONS | PA | | | YES | J8499 |
| XEMBIFY | IMMUNE GLOBULIN - SQ | IMMUNE DEFICIENCY | PA | | | YES | J1558 |
| XENAZINE | TETRABENAZINE | MISCELLANEOUS CNS DISORDERS | PA | | | YES | J8499 |
| XENICAL | ORLISTAT | WEIGHT LOSS | PA | | | YES | J3490 |
| XENPOZYME✦ | OLIPUDASE ALFA-RPCP | ENZYME DEFICIENCIES | | CPA | | YES | C9399, J3590 (J0218 EFF: 4/1/23) |
| XEOMIN | INCOTBULINUMTOXINA | NEUROMUSCULAR CONDITIONS | PA | | | YES | J0588 |
| XIAFLEX | COLLAGENASE CLOSTRIDIUM HIST. | MISCELLANEOUS SPECIALTY CONDITIONS | PA | | | YES | J0775 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.

| 1199 Brand Name | Generic Description | Disease State | PA Required (PA) | Client Prior Authorization Program (CPA) | Step Therapy | Claim Edit | Reimbursement Code |
|------------------------|----------------------------------|--------------------------|------------------|--|--------------|------------|--------------------|
| XOLAIR | OMALIZUMAB | RESPIRATORY CONDITIONS | PA | | | YES | J2357 |
| XULANE | NORELGESTROMIN/ETHINYL ESTRADIOL | CONTRACEPTIVE | | | | YES | J7304 |
| XYNTHA/XYNTHA SOLOFUSE | FACTOR VIII (ANTHEMOPHL FCTR) | HEMOPHILIA | | | | YES | J7185 |
| ZARXIO◆ | FILGRASTIM-SNDZ | BLOOD CELL DEFICIENCY | PA | | | YES | Q5101 |
| ZAVESCA | MIGLUSTAT | ENZYME DEFICIENCIES | | CPA | | NO | J8499 |
| ZEMAIRA | ALPHA-1-PROTEINASE INHIBITOR | RESPIRATORY CONDITIONS | PA | | | YES | J0256 |
| ZEPATIER | ELBASVIR/GRAZOPREVIR | HEPATITIS C | PA | | | YES | J8499 |
| ZILRETTA | TRIAMCINOLONE MICROSPHERES | OSTEOARTHRITIS | | | | YES | J3304 |
| ZINPLAVA | BEZLOTOXUMAB | INFECTIOUS DISEASE | | | | YES | J0565 |
| ZIRABEV◆ | BEVACIZUMAB | OPHTHALMIC CONDITIONS | PA | | | YES | Q5118 |
| ZOLADEX◆ | GOSERELIN ACETATE | ENDOCRINE DISORDERS | PA | | | YES | J9202 |
| ZOLEDRONIC ACID◆ | ZOLEDRONIC ACID | OSTEOPOROSIS | PA | | | YES | J3489 |
| ZOLGENSMA | ONASEMNOGENE ABEPARVOVEC-XIOI | NEUROMUSCULAR CONDITIONS | | CPA | | YES | J3399 |
| ZOMACTON | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| ZOMETA 4MG◆ | ZOLEDRONIC ACID | CANCER | PA | | | YES | J3489 |
| ZOMETA 5MG | ZOLEDRONIC ACID | OSTEOPOROSIS | PA | | | YES | J3489 |
| ZORBTVIE | SOMATROPIN | GROWTH DEFICIENCY | PA | | | YES | J2941 |
| ZULRESSO | BREXANOLONE | MISCELLANEOUS CONDITIONS | | CPA | | YES | J1632 |
| ZYNTEGLO | BETIBEGLOGENE | BLOOD CELL DEFICIENCY | | CPA | | YES | C9399, J3590 |

✦ Indicates a change from previous Drug List (i.e., new drug added to list, new Prior Authorization requirement or new reimbursement code).

◆ If the indication is CANCER, and the drug is subject to management by eviCore Comprehensive Oncology Management Program, please contact (888) 910-1199 for additional assistance. If the indication is NOT cancer, please contact CareContinuum for Prior Authorization.

★ Billing for any drug or biologic acquired with a 340B drug pricing program discount requires the use of JG or TB modifier effective 1/1/2018.

Claims where there is a Prior Authorization requirement will have claims checked against the quantities and approvals obtained in the Prior Authorization. Drug list is subject to change at any time in between quarterly updates.